/content/mofsl-website-adobe/fragments/open-demat-popup
style
hide-in-desktop

US Stock Details

Get in-depth insights on US stocks, including fundamentals, financials, shareholding, peer comparison, and performance. Track key metrics, price trends, and market sentiment for informed decisions. Stay ahead with expert analysis and data-driven strategies at Motilal Oswal.

style
pb-0

Akari Therapeutics PLC

us-stock
To Invest in {{usstockname}}
/content/mofsl-website-adobe/demat-form-fields
style
sticky-block,pt-0
us-stock
style
pt-0
$0.3147 -0.0156(-1.56%) AKTX at 04 Dec 2025 04:25 PM Biotechnology
Lowest Today 0.2918
Highest Today 0.3396
Today’s Open 0.33
Prev. Close 0.3454
52 Week High 1.73
52 Week Low 0.29
Day’s Range: Low 0.2918 High 0.3396
52-Week Range: Low 0.29 High 1.73
1 day return -
1 Week return -30.96
1 month return -57.17
3 month return -54.57
6 month return -73.83
1 year return -75.37
3 year return -97.11
5 year return -99.08
10 year return -

Institutional Holdings

Sabby Management LLC 0.55

Palo Alto Investors, LLC 0.45

HighTower Advisors, LLC 0.24

Omnia Family Wealth, LLC 0.19

HPM Partners LLC 0.07

Cresset Asset Management, LLC 0.06

Renaissance Technologies Corp 0.05

LUX IM Global Medtech HX 0.03

Accent Capital Management LLC 0.03

Goss Wealth Management LLC 0.02

UBS Group AG 0.01

RiverNorth Marketplace Lending Corp 0.00

RiverNorth Opportunities 0.00

Bank of America Corp 0.00

Royal Bank of Canada 0.00

Truvestments Capital LLC 0.00

Advisor Group Holdings, Inc. 0.00

Cornerstone Planning Group LLC 0.00

Morgan Stanley - Brokerage Accounts 0.00

SBI Securities Co Ltd 0.00

Market Status

Strong Buy: 1

Buy: 0

Hold: 0

Sell: 0

Strong Sell: 0

Fundamentals

Market Cap 16.96 M

PB Ratio 0.7662

PE Ratio 0.0

Enterprise Value 17.02 M

Total Assets 50.56 M

Volume 781549

Company Financials

Annual Revenue FY23:null 0.0M, FY22:0 0.0M, FY21:0 0.0M, FY20:0 0.0M, FY19:0 0.0M

Annual Profit FY23:-4000 -0.0M, FY22:null 0.0M, FY21:null 0.0M, FY20:null 0.0M, FY19:null 0.0M

Annual Net worth FY23:-10008000 -10.0M, FY22:-6972252 -7.0M, FY21:-17606856 -17.6M, FY20:-17597000 -17.6M, FY19:-21764000 -21.8M

Quarterly Revenue Q3/2025:0 0.0M, Q2/2025:0 0.0M, Q1/2025:25998 0.0M, Q3/2024:0 0.0M, Q2/2024:0 0.0M

Quarterly Profit Q3/2025:null 0.0M, Q2/2025:null 0.0M, Q1/2025:-1000 -0.0M, Q3/2024:null 0.0M, Q2/2024:null 0.0M

Quarterly Net worth Q3/2025:-6361564 -6.4M, Q2/2025:-1895000 -1.9M, Q1/2025:-3705000 -3.7M, Q3/2024:-2895000 -2.9M, Q2/2024:-7558000 -7.6M

Fund house & investment objective

Company Information Akari Therapeutics, Plc, an oncology company, develops next-generation antibody-drug conjugates (ADC) for cancer-killing toxins. Its lead payload is PH1 to disrupt the function of spliceosomes and to trigger an immune response that leads to additional cancer cell killing. The company's lead product candidate is AKTX-101, a preclinical stage trop2-targeting ADC that combines PH1 with the trop2 antibody to treat solid tumor cancer types, including lung, breast, colon, and prostate. Its payloads include PH5, which inhibits DNA mismatch repair (MMR) and DNA damage response (DDR) to generate neoepitopes, and PH6, which inhibits DNA transcription in cancer cells and co-opted immune cells. The company also develops AKTX-102, a novel bispecific ADC that utilizes PH1 as its payload to treat various solid tumor cancers. Akari Therapeutics, Plc is headquartered in Boston, Massachusetts.

Organisation Biotechnology

Employees 8

Industry Biotechnology

CEO Mr. Abizer Gaslightwala

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right
style
align-center,button-arrow